Mosaic Biosciences

Executive Summary

Mosaic Biosciences is a Boulder-based biologics discovery CRO that partners with biotech and pharmaceutical companies to advance antibody and protein therapeutics from target identification through candidate selection. Its integrated services cover antibody discovery, protein engineering, protein sciences, cell-based assays, and translational pharmacology. Founded in 2016, the company has established itself as a reliable partner in the competitive CRO landscape, serving clients across immunology and other therapeutic areas. As a private company, Mosaic does not disclose financials, but its focus on early-stage biologics positions it to benefit from the growing demand for outsourced drug discovery services. The company's stage classification as 'Phase 3' likely reflects its operational maturity rather than a clinical-stage asset, indicating a stable business with recurring revenue from service contracts. Mosaic's value proposition lies in its end-to-end capabilities and scientific expertise, which enable faster and more efficient antibody discovery for clients. While the CRO market faces pricing pressure and competition, Mosaic's niche focus and Boulder location provide access to top talent and a collaborative ecosystem. The company's growth prospects depend on securing larger partnerships and expanding its technology platform.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Major Partnership or Licensing Deal50% success
• TBDLaunch of New Technology Platform or Service Expansion60% success
• Q4 2026Completion of Series A or B Fundraising Round40% success